DSIP results: what to expect and when

An experimental sleep peptide with small, mixed human studies and no FDA-approved dose.

Also called: Delta sleep-inducing peptide, Delta-sleep-inducing peptide, Emideltide.

Sleep peptides · Experimental nine-amino-acid peptide with uncertain sleep-signaling targets.

A six-person sleep study tested acute IV doses; it does not establish a multiweek injection cycle.

51 primary human research reports are listed, including biomarkers and overlapping series. Sleep trials are small and mixed; no human subcutaneous trial was found.

Key studies

  • Healthy volunteers: morning infusion: Median sleep time during the next 130 minutes was 59% greater with DSIP than placebo. (source)
  • Early insomnia letter: No arm-level results were available in the retrieved record. (source)
  • Six adults with insomnia: Longer, less interrupted sleep was reported; benefit began in hour 2 and lasted up to 6 hours. (source)
  • Five early human experiments: Four evening doses reportedly normalized disturbed sleep; daytime tests suggested greater alertness. (source)
  • Insomnia after brain-stem injury: Baseline sleep was under 4 hours; DSIP improved sleep reversibly, without normalizing REM latency. (source)
  • Alcohol and opioid withdrawal pilot: 49 were evaluable; 48 improved: 22 alcohol patients and 26 of 27 opioid patients. (source)

Related to DSIP

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.